U.S. Proposes New Restrictions on Biotech Investments in China: What Businesses Need to Know
On October 22, 2026, the U.S. Treasury Department proposed new rules that would expand existing outbound investment restrictions to certain biotechnology activities involving China.
If finalized, the rules could prohibit some U.S. investments in Chinese biotech companies, potentially affecting fundraising, joint ventures, acquisitions, and cross-border research partnerships.
For businesses seeking U.S. capital or expanding internationally, the key question is whether their current deal structures could still work under the proposed rules.
Which Biotech Companies Could Be Affected?
The proposal could reach beyond traditional pharmaceutical and drug development companies. Potentially affected sectors include:
Biopharma: Drug development, vaccines, and cell and gene therapies.
Lab automation: Automated laboratory equipment, robotics, and cloud-based lab software.
Advanced biotechnology: Certain sequencing technologies, brain-computer interfaces, and bioinformatics tools.
Importantly, incorporating a company outside China would not automatically put it beyond the rules. Ownership and control structures could also matter.
The proposal is not yet final. Two dates are worth watching:
December 7, 2026: Public comment deadline.
March 13, 2027: Deadline for the Treasury Department to issue final rules.
The effective date has not yet been determined.
Could Your Financing or Partnership Be at Risk?
The proposed restrictions could affect several common cross-border business arrangements:
Equity investments: Certain direct investments by U.S. investors in covered Chinese biotech companies could be prohibited.
NewCo structures: Setting up a new company outside China may not avoid restrictions if its ownership or business arrangements fall within the rules.
Joint ventures and co-development: Partnerships involving shared resources, profits, or losses could face additional scrutiny.
What about technology licensing? A standalone licensing agreement generally would not be prohibited solely under this proposal. However, licensing deals that include equity interests, warrants, or certain profit-sharing and joint-development arrangements could raise concerns.
The bottom line: What matters is how a deal actually works, not simply what the agreement is called.
What Should Businesses Do Now?
Although the proposal has not taken effect, companies planning cross-border transactions should consider three steps:
Review pending deals. Identify investments, acquisitions, NewCo structures, and joint ventures that may be affected.
Examine deal terms. Pay particular attention to ownership, control, profit-sharing, and joint-development arrangements.
Plan ahead. Consider how the final rules and their effective date could affect transaction timelines and closing plans.
The proposal is not expected to apply retroactively to completed transactions. However, existing regulations may still apply.
Conclusion
For Chinese biotech and pharmaceutical companies, these proposed restrictions could affect more than access to U.S. funding. They may also influence how businesses structure international partnerships, license technology, and pursue global expansion.
A deal that makes commercial sense today also needs a legal structure that can withstand tomorrow's regulatory changes.
If your company is considering U.S.-China biotech investments, financing, licensing, joint ventures, or acquisitions, contact our team at contact@consultils.com to discuss your options.
Disclaimer: The materials provided on this website are for general informational purposes only and do not, and are not intended to, constitute legal advice. You should not act or refrain from acting based on any information provided here. Please consult with your own legal counsel regarding your specific situation and legal questions.
Maggie advises public and private companies on capital markets transactions, mergers and acquisitions, corporate governance, and strategic cross-border matters. Her experience includes initial public offerings (IPOs), reverse mergers, de-SPAC transactions, U.S. securities law compliance, Section 16 and Schedule 13G/D filings, shareholder activism, and takeover preparedness. She regularly counsels clients on complex corporate transactions and regulatory requirements in both the United States and China.
Prior to joining ILS, Maggie was a senior corporate attorney at Gibson, Dunn & Crutcher LLP, where she advised clients on a broad range of corporate and securities law matters. She earned her J.D. from University of California, Berkeley School of Law and was elected to the Order of the Coif.
Email: contact@consultils.com | Phone: 626-344-8949
Comments